{"transactions":[{"id":708296,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30140,"kind":"person","name":"Pauza Charles David","position":1,"cik":"0002018150","reported_name":"Pauza Charles David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Science Officer Virology"}}],"security":"Stock Option (right to buy)","published_at":"2026-07-16T16:39:47.000Z","date":"2026-07-09","kind":"grant","planned":false,"acquired":true,"shares":97000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date."}],"balance_after":97000,"derivative":{"exercise_price":0.68,"exercise_date":"2027-07-09","expiration_date":"2036-07-09","underlying":"Common Stock","underlying_shares":97000},"source":{"system":"sec-edgar","filing":"0002018150-26-000003","document":"form4-07162026_040743.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000201815026000003/form4-07162026_040743.xml","form_type":"4"}},{"id":851705,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30140,"kind":"person","name":"Pauza Charles David","position":1,"cik":"0002018150","reported_name":"Pauza Charles David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Science Officer Virology"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-10T23:18:25.000Z","date":"2026-03-08","kind":"grant","planned":false,"acquired":true,"shares":118367,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof.  The stock options under this award will vest 100% on the first anniversary of the grant date."}],"balance_after":118367,"derivative":{"exercise_price":1.6,"exercise_date":"2027-03-08","expiration_date":"2036-03-08","underlying":"Common Stock","underlying_shares":118367},"source":{"system":"sec-edgar","filing":"0002018150-26-000002","document":"form4-03102026_110321.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000201815026000002/form4-03102026_110321.xml","form_type":"4"}},{"id":968022,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30140,"kind":"person","name":"Pauza Charles David","position":1,"cik":"0002018150","reported_name":"Pauza Charles David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Science Officer Virology"}}],"security":"Stock Option (right to purchase)","published_at":"2025-12-16T23:16:22.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":73886,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest 100% on the first anniversary of the grant date."}],"balance_after":73886,"derivative":{"exercise_price":2.33,"exercise_date":"2026-12-12","expiration_date":"2035-12-12","underlying":"Common Stock","underlying_shares":73886},"source":{"system":"sec-edgar","filing":"0002018150-25-000004","document":"form4-12162025_111219.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000201815025000004/form4-12162025_111219.xml","form_type":"4"}},{"id":968021,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30140,"kind":"person","name":"Pauza Charles David","position":1,"cik":"0002018150","reported_name":"Pauza Charles David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Science Officer Virology"}}],"security":"Common Stock","published_at":"2025-12-16T23:16:22.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":18471,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units that will vest 100% on the first anniversary of the grant date. Each restricted stock unit will convert into shares of common stock on a one-for-one basis."}],"balance_after":115971,"source":{"system":"sec-edgar","filing":"0002018150-25-000004","document":"form4-12162025_111219.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000201815025000004/form4-12162025_111219.xml","form_type":"4"}},{"id":1018776,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30140,"kind":"person","name":"Pauza Charles David","position":1,"cik":"0002018150","reported_name":"Pauza Charles David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Science Officer Virology"}}],"security":"Stock Option (right to purchase)","published_at":"2025-10-16T00:08:46.000Z","date":"2025-10-12","kind":"grant","planned":false,"acquired":true,"shares":32406,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest 100% on the first anniversary of the grant date."}],"balance_after":32406,"derivative":{"exercise_price":3.01,"exercise_date":"2026-10-12","expiration_date":"2035-10-12","underlying":"Common Stock","underlying_shares":32406},"source":{"system":"sec-edgar","filing":"0002018150-25-000003","document":"form4-10162025_121042.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000201815025000003/form4-10162025_121042.xml","form_type":"4"}},{"id":1550721,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30140,"kind":"person","name":"Pauza Charles David","position":1,"cik":"0002018150","reported_name":"Pauza Charles David","relationship":{"officer":true,"officer_title":"Chief Science Officer Virology"}}],"security":"Stock Option (right to purchase)","published_at":"2024-04-04T00:04:16.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":503227,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On April 1, 2024, the Company acquired Trawsfynydd Therapeutics, Inc. (\"Trawsfynydd\") in accordance with the terms of an Agreement and Plan of Merger, dated April 1, 2024 (the \"Merger Agreement\"), by and among the Company, Traws Merger Sub I, Inc., Traws Merger Sub II, LLC, and Trawsfynydd (the \"Merger\"). Upon consummation of the Merger, all of the outstanding shares of common stock of Trawsfynydd were converted into shares of Common Stock on a 1:20.1291 basis pursuant to the terms of the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Received in the Merger in exchange for stock options to acquire 25,000 shares of Trawsfynydd common stock with an exercise price of $0.0001 per share."}],"balance_after":503227,"derivative":{"exercise_price":0.01,"exercise_date":"2023-11-01","expiration_date":"2033-10-31","underlying":"Common Stock","underlying_shares":503227},"source":{"system":"sec-edgar","filing":"0000929638-24-001364","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000092963824001364/form4.xml","form_type":"4"}},{"id":1550720,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30140,"kind":"person","name":"Pauza Charles David","position":1,"cik":"0002018150","reported_name":"Pauza Charles David","relationship":{"officer":true,"officer_title":"Chief Science Officer Virology"}}],"security":"Stock Option (right to purchase)","published_at":"2024-04-04T00:04:16.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":333136,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On April 1, 2024, the Company acquired Trawsfynydd Therapeutics, Inc. (\"Trawsfynydd\") in accordance with the terms of an Agreement and Plan of Merger, dated April 1, 2024 (the \"Merger Agreement\"), by and among the Company, Traws Merger Sub I, Inc., Traws Merger Sub II, LLC, and Trawsfynydd (the \"Merger\"). Upon consummation of the Merger, all of the outstanding shares of common stock of Trawsfynydd were converted into shares of Common Stock on a 1:20.1291 basis pursuant to the terms of the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Received in the Merger in exchange for stock options to acquire 16,550 shares of Trawsfynydd common stock with an exercise price of $1.38 per share."}],"balance_after":333136,"derivative":{"exercise_price":0.07,"exercise_date":"2023-11-01","expiration_date":"2033-10-31","underlying":"Common Stock","underlying_shares":333136},"source":{"system":"sec-edgar","filing":"0000929638-24-001364","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000092963824001364/form4.xml","form_type":"4"}},{"id":1550719,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":30140,"kind":"person","name":"Pauza Charles David","position":1,"cik":"0002018150","reported_name":"Pauza Charles David","relationship":{"officer":true,"officer_title":"Chief Science Officer Virology"}}],"security":"Common Stock","published_at":"2024-04-04T00:04:16.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":97500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents an award of restricted stock units that will vest in four equal annual installments beginning April 1, 2025.  Each restricted stock unit will convert into shares of common stock of Traws Pharma, Inc. (f/k/a Onconova Therapeutics, Inc., the \"Company\"), par value $0.01 per share (\"Common Stock\"), on a one-for-one basis."}],"balance_after":97500,"source":{"system":"sec-edgar","filing":"0000929638-24-001364","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000092963824001364/form4.xml","form_type":"4"}}]}